Neuroendocrine Tumors - Imaging Abdominal Complications Abstract #168

Introduction: Neuroendocrine tumors mostly arise from the gastrointestinal tract and pancreas but also from bronchopulmonary or any other organ. Abdominal complications are usually associated with the primary GI tract tumor.
Aim(s): Abdominal complications can include: local invasion, growing mass, metastases development and symptoms following overproduction of bioactive amines.
Materials and methods: The authors seek to illustrate the spectrum of these complications using data from the Outpatient NETS Group of our Institution, emphasizing the correlation of different imaging methods applied: barium contrast studies, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic studies and Positron Emission Tomography (PET).
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Joana Ip
Authors: Ip J, Claro I, Duarte I

To read results and conclusion, please login ...

Further abstracts you may be interested in

#35 Primary Hyperparathyroidism in patients with gastric carcinoid Tumors type-1: an unusual coexistence
Introduction: Although a number of familiar endocrine syndromes are associated with primary hyperparathyroidism (PHP), there is no information regarding its prevalence in other sporadic neuroendocrine diseases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dimitrios Thomas
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis
#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#143 Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors
Introduction: In the absence of preoperative somatostatin receptor (sst) scans, knowledge of immunohistochemical sst2 tumor expression may help in predicting the success of somatostatin analogue-based follow-up studies and treatment of neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Karsten Müssig
#370 Postoperative Complications after Previous Peptide-Receptor Radionuclide Therapy
Introduction: Treatment with radiation or chemotherapy can result in a higher rate of postoperative complications.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Daniel Kaemmerer